Hepatic uptake and excretion of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans.

@article{Umehara2008HepaticUA,
  title={Hepatic uptake and excretion of (-)-N-\{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl\}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans.},
  author={Ken-Ichi Umehara and Megumi Iwai and Yasuhisa Adachi and Takafumi Iwatsubo and Takashi Usui and Hidetaka Kamimura},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2008},
  volume={36 6},
  pages={1030-8}
}
(-)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel "funny" If current channel (If channel) inhibitor, is being developed as a treatment for stable angina and atrial fibrillation. The hepatic uptake/excretion of YM758 was clarified using transporter-expressing mammalian cells and hepatocytes mainly in humans and partly in rats. cDNA-expressing human embryonic kidney 293 cells were used to determine that YM758 was greatly… CONTINUE READING